Francesco Spagnolo
A5057849200- Cancer Immunotherapy and Biomarkers
- Diabetes Treatment and Management
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Colorectal Cancer Treatments and Studies
- Metabolism, Diabetes, and Cancer
- Nonmelanoma Skin Cancer Studies
- Brain Metastases and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Ocular Oncology and Treatments
- Immune cells in cancer
- Economic and Financial Impacts of Cancer
- Computational Drug Discovery Methods
- Lung Cancer Treatments and Mutations
- Click Chemistry and Applications
- Advanced Breast Cancer Therapies
- Cancer and Skin Lesions
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
Ospedale Policlinico San Martino
2016-2025
University of Genoa
2017-2024
Azienda Ospedaliera Pugliese Ciaccio
2022-2024
Alleanza Contro il Cancro
2012-2020
Ospedale San Paolo
2019
Istituti di Ricovero e Cura a Carattere Scientifico
2012-2017
National Cancer Research Institute
2016
Queen Mary University of London
2015
Mater Hospital
2015
Azienda Ospedaliera Universitaria Senese
2014
Clinical responses to ipilimumab are variable in terms of onset, magnitude and duration. Upfront identification patients who more likely or unlikely benefit from treatment is a major need.Prospectively collected data 720 advanced melanoma treated with 3 mg/kg within the Italian expanded access program were analyzed. The derived neutrophil-to-lymphocyte ratio (dNLR) was calculated baseline peripheral blood cell counts, receiver operating characteristic curve used evaluate best cutoff for this...
Background Concomitant medications, such as steroids, proton pump inhibitors (PPI) and antibiotics, might affect clinical outcomes with immune checkpoint inhibitors. Methods We conducted a multicenter observational retrospective study aimed at evaluating the impact of concomitant medications on outcomes, by weighing their associations baseline characteristics (including performance status, burden disease body mass index) underlying causes for prescription. This analysis included consecutive...
Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma.SECOMBIT is a randomized, three-arm, noncomparative phase II trial (ClinicalTrials.gov identifier: NCT02631447). Patients with untreated, melanoma from 37 sites in nine countries were randomly assigned to arm A (encorafenib [450 mg orally once daily] plus binimetinib [45 twice until progressive disease [PD] -> ipilimumab nivolumab [ipilimumab 3 mg/kg every weeks...
Abstract No prospective data were available prior to 2021 inform selection between combination BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) cytotoxic T lymphocyte antigen-4 (CTLA-4) as first-line treatment options for BRAFV 600-mutant melanoma. SECOMBIT (NCT02631447) was a randomized, three-arm, noncomparative phase II trial in which patients randomized one two sequences with immunotherapy or targeted therapy first, third arm an 8-week induction...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. Pembrolizumab adjuvant therapy was shown significantly improve recurrence-free survival (RFS) and distant...
In recent years, advances in melanoma treatment have renewed patient hope. This comprehensive review emphasizes the evolving landscape, particularly highlighting first-line strategies and interplay between immune-checkpoint inhibitors (ICIs) targeted therapies. Ipilimumab plus nivolumab has achieved best median overall survival, exceeding 70 months. However, introduction of new ICIs, like relatlimab, added complexity to therapy decisions. Our aim is guide clinicians making personalized...
Ipilimumab plus nivolumab (COMBO) is the standard treatment in asymptomatic patients with melanoma brain metastases (MBM). We report a retrospective study aiming to assess outcome of MBM treated COMBO outside clinical trials.
Abstract Patients with melanoma brain metastases have a poor prognosis and historically been excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity to evaluate the feasibility of ipilimumab (3 mg/kg every 3 weeks for four doses) in patients stage (unresectable) or 4 asymptomatic metastases, who had failed did not tolerate previous treatments no other therapeutic option available. Tumor assessments were conducted at baseline week 12 using immune-related...
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free (PFS). We used targeted transcriptomics subset explore differences the tumor microenvironment (TME) or...